quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:09:29·1702d
ANALYSTRating
Catabasis Pharmaceuticals, Inc. logo

Catabasis Pharmaceuticals upgraded by HC Wainwright & Co. with a new price target

CATB· Catabasis Pharmaceuticals, Inc.
Health Care
Original source

Companies

  • CATB
    Catabasis Pharmaceuticals, Inc.
    Health Care

Recent analyst ratings

  • Sep 2UpdateWedbush$16.00
  • Aug 25UpdateHC Wainwright & Co.$13.00

Related

  • 13D/G1674d
    SEC Form SC 13D/A filed by Catabasis Pharmaceuticals, Inc. (Amendment)
  • INSIDER1674d
    SEC Form 4 filed by Violin Jonathan
  • 13D/G1674d
    SEC Form SC 13G/A filed by Catabasis Pharmaceuticals, Inc. (Amendment)
  • SEC1688d
    Catabasis Pharmaceuticals, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR1688d
    Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
  • ANALYST1694d
    Wedbush initiated coverage on Catabasis Pharmaceuticals with a new price target
  • SEC1707d
    Catabasis Pharmaceuticals, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
  • SEC1718d
    SEC Form S-8 filed by Catabasis Pharmaceuticals, Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022